SCHEMBL4670745

SCHEMBL4670745

O=C(O)C(O)=CC(=O)c1ccc(S(=O)(=O)c2ccc(F)cc2)[nH]1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
AKR1C3 P42330 1/20 0.36
MMP1 P03956 2/20 0.33
MMP2 P08253 2/20 0.33
MMP9 P14780 2/20 0.33
MMP13 P45452 2/20 0.33
MMP3 P08254 1/20 0.33
MMP12 P39900 1/20 0.33
MMP14 P50281 1/20 0.33
MAPT P10636 1/20 0.33
KDM4E B2RXH2 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
BRAF P15056 1/20 0.32
HSD11B1 P28845 2/20 0.32
AKR1B1 P15121 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
MMP8 P22894 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4670742 1.00 PTGS2 (0.36) PTGS2AKR1C2AKR1C1AKR1C3MMP1
SCHEMBL4678633 0.87 HTR6 (0.37) MAPTL3MBTL1GAA
SCHEMBL4678628 0.87 HTR6 (0.37) MAPTL3MBTL1GAA
SCHEMBL4676230 0.86 ALDH1A1 (0.40) AKR1C2AKR1C1AKR1C3MMP1MMP2
SCHEMBL4676224 0.86 ALDH1A1 (0.40) AKR1C2AKR1C1AKR1C3MMP1MMP2
SCHEMBL4671350 0.77 MAPT (0.38) PTGS2AKR1C2AKR1C1AKR1C3MMP1
SCHEMBL4671347 0.77 MAPT (0.38) PTGS2AKR1C2AKR1C1AKR1C3MMP1
SCHEMBL4674849 0.76 PTGS2 (0.38) PTGS2AKR1C2AKR1C1AKR1C3MAPT
SCHEMBL4674846 0.76 PTGS2 (0.38) PTGS2AKR1C2AKR1C1AKR1C3MAPT
SCHEMBL4677419 0.75 AKR1B1 (0.47) PTGS2AKR1C2AKR1C1AKR1C3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PTGS2 4586/4885AKR1C2 24/4885AKR1C1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.